Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Surgical Site Infection
Interventions
DRUG

Vancomycin

Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.

Trial Locations (7)

2501

Spitalzentrum Biel, Biel

3010

University Hostpital Bern, Department of Neurosurgery, Bern

University Hostpital Bern, Department of orthopaedy, Bern

3012

Lindenhofspital Bern, Bern

6006

Klinik St. Anna, Lucerne

8091

University Hospital Zurich, Department of Neurosurgery, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
collaborator

University Hospital Freiburg

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER